Cytovia Therapeutics Files New Patents for its Natural Killer Cell Engager Multifunctional Antibodies (FLEX-NK®) for the Treatment of Hematological and Solid Tumors First-in-class NK Engager multifunctional antibody products can activate patients’ own NK cells or be combined with Cytovia’s off-the-shelf Universal iPSC-derived NK Cells
April 12, 2021 11:11 ET | Source: Cytovia Therapeutics Cytovia Therapeutics Miami, Florida, UNITED STATES
CAMBRIDGE, Mass. and AVENTURA, Fla., April 12, 2021 (GLOBE NEWSWIRE) Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic “off-the-shelf” gene-edited Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs) and NK cell engager multifunctional antibodies, announced today that it has filed two provisional composition of matter patent applications for its FLEX-NK® platform, consisting of NKp46-based NK cell e